Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion

Journal of Cancer Research and Clinical Oncology

Volumn 129, Issue 7, 2003, Pages 383-391

  Zavrski, Ivana ^a   Naujokat, Cord ^b   Niemöller, Kathrin ^a   Jakob, Christian ^a   Heider, Ulrike ^a   Langelotz, Corinna ^a   Fleissner, Claudia ^a   Eucker, Jan ^a   Possinger, Kurt ^a   Sezer, Orhan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Apoptosis; Multiple myeloma; Proteasome; Proteasome inhibitors

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CD34 ANTIGEN; KI 67 ANTIGEN; LACTACYSTIN; LIPOCORTIN 5; MG 262; PROTEASOME INHIBITOR; PROTEIN PSI; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL GROWTH; CHROMOSOME 13; CHROMOSOME DELETION 13; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PLASMA CELL; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; STAINING; STEM CELL;

ANTIGENS, CD34; APOPTOSIS; CASPASE 3; CASPASE 7; CASPASES; CELL CYCLE; CELL DIVISION; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 13; CYSTEINE ENDOPEPTIDASES; HEMATOPOIETIC STEM CELLS; HUMANS; MULTIENZYME COMPLEXES; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; TUMOR CELLS, CULTURED;

EID: 0043164960     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-003-0454-6     Document Type: Article

References (47)

1. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma YT, Plamondon L, Stein RL (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8:333-338
2. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615-2622
3. Adams J, Palombella VJ, Eliott PJ (2000) Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 18:109-121
4. WAF1/CIP1 expression. Biochem Biophys Res Com 227:564-569
5. Boyer SN, Wazer DE, Band V (1996) E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 56:4620-4624
6. Casaccia-Bonnefil P, Tikoo R, Kiyokawa H, Friedrich V Jr, Chao MV, Koff A (1997) Oligodendrocyte precusor differentiation is preturbed in the absence of the cyclin-dependent kinase inhibitor p27Kip1. Genes Dev 11:2335-2346
7. Dick LR, Cruickshank AA, Grenier L, Melandri FD, Nunes SL, Stein RL (1996) Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin beta-lactone. J Biol Chem 271:7273-7276
8. Dick LR, Cruikshank AA, Destree AT, Grenier L, McCormack TA, Melandri FD, Nunes SL, Palombella VJ, Parent LA, Plamondon L, Stein RL (1997) Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J Biol Chem 272:182-188
9. Domenech J, Georget MT, Gihana E, Colombat P, Bremond JL, Chassaigne M, Lamagnere JP, Binet C (1992) Evaluation of doxorubicin in combination with mafosfamide for in vitro elimination of myeloid and lymphoid tumor cells from human bone marrow. Bone Marrow Transplant 9:101-106
10. Drexler HC (1997) Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 94:855-860
11. Endl E, Gerdes J (2000) Posttranslational modifications of the KI-67 protein coincide with two major checkpoints during mitosis. J Cell Physiol 182:371-380
12. Fujisawa T, Watanabe J, Akaboshi M, Ohno E, Kuramoto H (2001) Immunohistochemical study on VEGF expression in endometrial carcinoma - comparison with p53 expression, angiogenesis, and tumor histologic grade. J Cancer Res Clin Oncol 127:668-674
13. Fuse T, Tanikawa M, Nakanishi M, Ikeda K, Tada T, Inagaki H, Asai K, Kato T, Yamada K (2000) p27Kip1 expression by contact inhibition as a prognostic index of human glioma. J Neurochem 74:1393-1399
14. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715
15. Ghielmini M, Colli E, Bosshard G, Pennella G, Geroni C, Torri V, D'Incalci M, Cavalli F, Sessa C (1998) Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyl-doxorubicin and its metabolites. Cancer Chemother Pharmacol 42:235-240
16. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076
17. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277:16639-16647
18. King RW, Deshaies RJ, Peters JM, Kirschner MW (1996) How proteolysis drives the cell cycle. Science 274:1652-1659
19. Kitagawa H, Tani E, Ikemoto H, Ozaki I, Nakano A, Omura S (1999) Proteasome inhibitors induce mitochondria independent apoptosis in human glioma cells. FEBS Lett 443:181-186
20. Komuro H, Kaneko S, Kaneko M, Nakanishi Y (2001) Expression of angiogenic factors and tumor progression in human neuroblastoma. J Cancer Res Clin Oncol 127:739-743
21. Kumeda SI, Deguchi A, Toi M, Omura S, Umezawa K (1999) Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells. Anticancer Res 19:3961-3968
22. Li B, Dou QP (2000) Bax degradation by the ubiquitin/ proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 97:3850-3855
23. Machiels BM, Henfling ME, Gerards WL, Broers JL, Bloemendal H, Ramaekers FC, Schutte B (1997) Detailed analysis of cell cycle kinetics upon proteasome inhibition. Cytometry 28:243-252
24. Maehara Y, Anai H, Tamada R, Sugimachi K (1987) The ATP assay is more sensitive than the succinate dehydrogenase inhibition test for predicting cell viability. Eur J Cancer Clin Oncol 23:273-276
25. Maki CG, Huibregtse JM, Howley PM (1996) In vivo ubiquitination and proteasome mediated degradation of p53. Cancer Res 56:2649-2654
26. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC (2002a) Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 99:4079-4086
27. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC (2002b) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 99:14374-14379
28. Naujokat C, Sezer O, Zinke H, Leclere A, Hauptmann S, Possinger K (2000) Proteasome inhibitors induce caspase-dependent apoptosis and accumulation of p21 WAF1/Cip1 in human immature leukemic cells. Eur J Haematol 65:221-236
29. Naujokat C, Hoffmann S (2002) Role and function of the 26S proteasome in proliferation and apoptosis. Lab Invest 82:965-980
30. Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, Elliott P, Adams J, McConkey DJ (2002) Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 1:1243-1253
31. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37-43
32. Niemöller K, Jakob C, Heider U, Zavrski I, Eucker J, Kaufmannn O, Possinger K, Sezer O (2003) Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III. J Cancer Res Clin Oncol 129:234-238
33. Orlowski RZ (1999) The ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 6:303-313
34. Orlowski M, Cardozzo C, Michaud C (1993) Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain an small neutral amino acids. Biochemistry 32:1563-1572
35. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M (1995) Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin dependent kinase inhibitor p27. Science 269:682-685
36. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T (1994) The ubiquitin-proteasome pathway is required for processing the NF-κB1 precusor protein and the activation of NF-κB. Cell 78:773-785
37. San Miguel JF, Blade Creixenti J, Garcia-Sanz R (1999) Treatment of multiple myeloma. Haematologica 84:36-58
38. Schluter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, Gerdes J (1993) The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 123:513-522
39. Schmid I, Cole SW, Korin YD, Zack JA, Giorgi JV (2000) Detection of cell cycle subcompartments by flow cytometric estimation of DNA-RNA content in combination with dual color immunofluorescence. Cytometry 39:108-116
40. Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A, Morris C, Tricot G, Epstein J, Barlogie B (2000) High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 96:1505-1511
41. Taniguchi T, Endo H, Chikatsu N, Uchimaru K, Asano S, Fujita T, Nakahata T, Motokura T (1999) Expression of p21(Cip1/Waf1/Sdi1) and p27(Kip1) cyclin-dependent kinase inhibitors during human hematopoiesis. Blood 93:4167-4178
42. Traenckner EB, Wilk S, Baeuerle PA (1994) A proteasome inhibitor prevents activation of NF-κB and stabilizes a newly phosphorylated form of I κB-α that is still bound to NF-κB. EMBO 13:5433-5441
43. Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Naucke S, Mattox S, Bracy D, Munshi N, Barlogie B (1997) Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 15:2659-2666
44. Tsurusawa M, Fujimoto T (1995) Cell cycle progression and phenotypic modification of Ki-67 antigen-negative G1- and G2-phase cells in phorbol ester-treated Molt-4 human leukemia cells. Cytometry 20:146-153
45. Wu Y, Luo H, Kanaan N, Wu J (2000) The proteasome controls the expression of a proliferation-associated nuclear antigen Ki-67. J Cell Biochem 76:596-604
46. Yamada Y, Sugahara K, Tsuruda K, Nohda K, Mori N, Hata T, Maeda T, Hayashibara T, Joh T, Honda M, Tawara M, Tomonaga M, Miyazaki Y, Kamihira S (2000) Lactacystin activates FLICE (caspase 8) protease and induces apoptosis in Fas-resistant adult T-cell leukemia cell lines. Eur J Haematol 64:315-322
47. Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E, Kaufmann H, Riedl L, Gisslinger H, Schreiber S, Heinz R, Ludwig H, Huber H, Drach J (2000) Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 95:1925-1930